KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Assets (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Assets for 18 consecutive years, with $5.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Assets rose 21.73% year-over-year to $5.1 billion; the TTM value through Mar 2026 reached $5.1 billion, up 21.73%, while the annual FY2025 figure was $5.0 billion, 17.13% up from the prior year.
  • Assets hit $5.1 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $5.0 billion in the prior quarter.
  • Across five years, Assets topped out at $5.1 billion in Q1 2026 and bottomed at $3.3 billion in Q2 2022.
  • Average Assets over 5 years is $4.0 billion, with a median of $3.8 billion recorded in 2023.
  • Year-over-year, Assets decreased 5.1% in 2022 and then rose 21.73% in 2026.
  • Alnylam Pharmaceuticals' Assets stood at $3.5 billion in 2022, then increased by 7.99% to $3.8 billion in 2023, then rose by 10.71% to $4.2 billion in 2024, then rose by 17.13% to $5.0 billion in 2025, then increased by 3.29% to $5.1 billion in 2026.
  • According to Business Quant data, Assets over the past three periods came in at $5.1 billion, $5.0 billion, and $4.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.